MedPath

Pregnancy in GUCH Patients

Not Applicable
Not yet recruiting
Conditions
Pregnancy Related
Infant Development
IUGR
Fetal Growth Restriction
Congenital Heart Disease
Interventions
Diagnostic Test: Neurodevelopmental assessment
Registration Number
NCT06574386
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Brief Summary

This study aims to investigate the impact of congenital heart diseases on maternal and foetal-neonatal health, the effect of pregnancy on maternal cardiac health, and the outcome of newborns/children born from Grown-Up Congenital Heart (GUCH) mothers with follow-up at one year, extendable to two.

The main question it aims to answer is:

-Does maternal congenital heart disease affects outcomes of newborn?

Detailed Description

After being informed about the study and potential risks all patients giving written informed consent will undergo:

* Cardiological and obstetric evaluation in the first trimester of pregnancy;

* Cardiological and obstetric revaluation in the second trimester of pregnancy;

* Cardiological and obstetric revaluation in the third trimester of pregnancy;

* Cardiac and general neonatal evaluation at birth;

* 2-year follow-up: maternal and neonatal cardiology evaluation, childhood neurodevelopment evaluation

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
70
Inclusion Criteria
  • Congenital heart disease in natural history or undergoing corrective and/or palliative cardiothoracic surgery.
  • Chronological age > 18 years.
  • Single pregnancy progressing normally at a gestational age of 14 weeks + 0.
  • Correct pregnancy dating based on CRL as per ISUOG guidelines. (26)
  • Normal results of non-invasive screening tests for foetal aneuploidies.
  • Normal first-trimester ultrasound examination.
  • Informed consent of the woman.
Exclusion Criteria
  • Maternal chromosomal abnormalities.
  • Maternal syndromic conditions.
  • Spontaneous abortion.
  • Vanishing Twin.
  • High risk for chromosomal abnormalities on screening tests performed in the 1st Trimester (Combined Test/NIPT) or Major foetal structural anomalies identified during first-trimester ultrasound evaluation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Childhood neurodevelopmentNeurodevelopmental assessmentNewborns from mothers with congenital heart disease will be subjected to neurodevelopmental assessment
Primary Outcome Measures
NameTimeMethod
Neonatal outcomes in terms of weight and appropriate intrauterine developmentAssessment in the first, second and third trimester of pregnancy

Observation of neonatal outcome in terms of incidence of foetal growth restriction (FGR), defined as deviation from genetic potential with neonates classified as small for gestational age (SGA) or adequate for gestational age (AGA).

Secondary Outcome Measures
NameTimeMethod
Physical examination of the mother (BMI)Assessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

Physical examination will be evaluated by weight and height combination to report BMI in kg/m\^2

Systolic and diastolic blood pressure of the mother during pregnancyAssessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

Systolic an diastolic blood pressure will be evaluated in mmHg

NYHA class progression during pregnancy (NYHA functional class)Assessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

NYHA class will be evalueted by medical examination during pregnancy

Cardiologic assessment of the mother (Electrocardiogram):Assessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

Cardiologic assesment will be evaluated by the use of Electrocardiogram (PR, QRS, QTc intervals and ST segment changes).

Cardiologic assesment of the mother (Echocardiography)Assessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

Cardiologic assesment will be evaluated by the use of echocardiography (wall motion assessment and residual congenital heart disease),

Cardiologic assesment of the mother (24-hour Holter ECG)Assessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

Cardiologic assesment will be evaluated by the use of 24-hour Holter ECG (ventricular and atrial arrhythmic burden)

Cardiologic assesment of the mother (24-hour Holter BP)Assessment in the first, second and third trimester of pregnancy. Follow-up at 1 and 2 year from childbirth

Cardiologic assesment will be evaluated by the use of 24-hour Holter BP (degree of arterial hypertension).

Assessment of foetal growth and weight (Subcutaneous Adipose Thickness SCAT)Assessment in the first, second, third trimester of pregnancy, and at delivery. Follow-up at 1/2 years after delivery.

Evaluated by abdominal adipose thickness index

Assessment of foetal oxygenationAssessment in the first, second, third trimester of pregnancy, and at delivery. Follow-up at 1/2 years after delivery.

Foetal oxygenation will be evaluated by rterial doppler of uterine arteries, umbilical arteries and middle cerebral artery and venous doppler of the umbilical vein and ductus venosus

Numbers of obstetric and maternal complicationsAssessment in the first, second, third trimester of pregnancy, and at delivery. Follow-up at 1/2 years after delivery.

Incidence of obstetric and maternal complications (maternal mortality, cardiac complications, hypertensive disorders, gestational diabetes, hepatosis, sepsis, placental abruption, thromboembolic events, postpartum haemorrhage, disseminated intravascular coagulation, need for further hospitalization; evaluation of mode of delivery)

Cardiological evaluation of the fetusAssessment in the first, second, third trimester of pregnancy, and at delivery. Follow-up at 1/2 years after delivery.

Cardiological evaluation of the fetus will be evaluated by foetal cardiotocography

Physical examination in newbornsPerformed at birth, three months, and twelve months of age. Follow-up at 1/2 years after birth

Physical examination will be evaluated by weight and height combination to report BMI in kg/m\^2

Newborn's health and vital signsAt birth

Evaluated by Apgar score calculation

Fetal metabolic conditionAt birth

Evaluated by umbilical artery blood gas analysis

Cardiologic assessment in newborns (Electrocardiogram)Performed at birth, three months, and twelve months of age. Follow-up at 1/2 years after birth.

Cardiologic assesment will be evaluated by the use of Electrocardiogram (PR, QRS, QTc intervals and ST segment changes).

Cardiologic assesment in newborns (Echocardiography)Performed at birth, three months, and twelve months of age. Follow-up at 1/2 years after birth.

Cardiologic assesment will be evaluated by the use of echocardiography (will be examined cardiac anatomical assessment; functional evaluation with left ventricular diastolic function and systolic function (EF and FS); right ventricular function; global function (MPI), PFO, PDA, pulmonary artery pressure, cardiac output, and input)

Neurological examination in newbornsPerformed at birth, three months, and twelve months of age. Follow-up at 1/2 years after birth.

Neurological evaluation will include cerebral ultrasound

Neurodevelopmental assessment in newborns (Hammersmith Infant Neurological Examination)Performed at birth, three months, and twelve months of age. Follow-up at 1/2 years after birth.

Neurological examination according to the Hammersmith Neonatal Neurological Examination

Physical growth in newborns (BMI)Performed at birth, three months, and twelve months of age.

Weight and height will be combined to report BMI in kg/m\^2

Physical growth in newborns (head circumference in Cm)Performed at birth, three months, and twelve months of age.

It will be measured head circumference in centimeters

Respiratory function in newbornsPerformed at birth, three months, and twelve months of age.

Performed pulmonary function tests and nitrogen washout.

Trial Locations

Locations (1)

Fondazione universitaria policlinico Agostino Gemelli

🇮🇹

Roma, Italy

© Copyright 2025. All Rights Reserved by MedPath